Biogen (BIIB) Cash from Financing Activities (2009 - 2026)

Biogen's Cash from Financing Activities history runs 18 years deep, the most recent figure standing at $1.3 billion for Q2 2026.

• In Q2 2026, Cash from Financing Activities rose 11176.92% year-over-year to $1.3 billion; the TTM figure through Jun 2026 stood at $985.0 million (up 3049.1% YoY), while the FY2025 annual figure was -$301.9 million, up 55.83% from the prior year.
• Cash from Financing Activities for Q2 2026 stood at $1.3 billion, up from -$43.8 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $1.3 billion in Q2 2026, with the low at -$1.3 billion in Q3 2022.
• The 5-year median for Cash from Financing Activities is -$33.2 million (2023), against an average of -$74.0 million.
• The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities slumped 8631.08% in 2023, then jumped 11176.92% in 2026.
• Biogen's Cash from Financing Activities stood at -$7.4 million in 2022, then plunged by 8631.08% to -$646.1 million in 2023, then surged by 101.22% to $7.9 million in 2024, then plunged by 1834.18% to -$137.0 million in 2025, then soared by 1045.99% to $1.3 billion in 2026.
• Business Quant data shows BIIB's Cash from Financing Activities at $1.3 billion in Q2 2026, -$43.8 million in Q1 2026, and -$137.0 million in Q4 2025.